<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis"><meta name="DC.contributor" content="Joseph Wettstein" scheme="inventor"><meta name="DC.contributor" content="Aventis Pharmaceuticals Inc." scheme="assignee"><meta name="DC.date" content="2002-4-1" scheme="dateSubmitted"><meta name="DC.description" content="The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis."><meta name="DC.date" content="2004-9-21" scheme="issued"><meta name="DC.relation" content="EP:0896537:A1" scheme="references"><meta name="DC.relation" content="US:20020006945:A1" scheme="references"><meta name="DC.relation" content="US:20020022646:A1" scheme="references"><meta name="DC.relation" content="US:4061767" scheme="references"><meta name="DC.relation" content="US:4087535" scheme="references"><meta name="DC.relation" content="US:4284784" scheme="references"><meta name="DC.relation" content="US:4284786" scheme="references"><meta name="DC.relation" content="US:4351841" scheme="references"><meta name="DC.relation" content="US:4965276" scheme="references"><meta name="DC.relation" content="US:4965278" scheme="references"><meta name="DC.relation" content="US:5268382" scheme="references"><meta name="DC.relation" content="US:5459163" scheme="references"><meta name="DC.relation" content="US:5679709" scheme="references"><meta name="DC.relation" content="US:5714514" scheme="references"><meta name="DC.relation" content="US:5780592" scheme="references"><meta name="DC.relation" content="US:5856330" scheme="references"><meta name="DC.relation" content="US:5981536" scheme="references"><meta name="DC.relation" content="US:5990141" scheme="references"><meta name="DC.relation" content="US:6011051" scheme="references"><meta name="DC.relation" content="US:6060494" scheme="references"><meta name="DC.relation" content="US:6133301" scheme="references"><meta name="DC.relation" content="WO:1993018776:A1" scheme="references"><meta name="DC.relation" content="WO:1994024095:A1" scheme="references"><meta name="DC.relation" content="WO:2000033876:A1" scheme="references"><meta name="citation_reference" content="Amitabh Prakash, et al., &quot;Leflunomide, A Review of its Use in Active Rheumatoid Arthritis&quot;, (1999), Drugs, vol. 58 (6), pp. 1137-1164."><meta name="citation_reference" content="Anthony S. Fauci, et al., &quot;Mutliple Sclerosis and Other Demyelinating Disease&quot;, in Harrison&#39;s Principles of Internal Medicine, 14&lt;th &gt;Edition, (1994), vol. 2, pp. 2409-2419, McGraw-Hill, New York."><meta name="citation_reference" content="Anthony S. Fauci, et al., “Mutliple Sclerosis and Other Demyelinating Disease”, in Harrison&#39;s Principles of Internal Medicine, 14th Edition, (1994), vol. 2, pp. 2409-2419, McGraw-Hill, New York."><meta name="citation_reference" content="Arvana Tablets, Prescription information, Apr. 2002.*"><meta name="citation_reference" content="Bertolini, Giorgio et al., A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppresive Drug, J. Med. Chem. 1997, pp. 2011-2016, vol. 40."><meta name="citation_reference" content="C. Bolton, &quot;Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment&quot;, (1995), Multiple Sclerosis, vol. 1, pp. 143-149."><meta name="citation_reference" content="Holly M. Cherwinski, et al., &quot;The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism&quot;, (1995),J. Pharmacol. Exp. Therap., vol. 272 (1), pp. 460-468."><meta name="citation_reference" content="J.M. Bruneau, et al., &quot;Purification of Human Dihydro-Orotate Dehydrogenase and Its Inhibition by A77 1726, the Active Metabolite of Leflunomide&quot;, Biochem. J. (1998), vol. 336, pp. 299-303."><meta name="citation_reference" content="Kaplan, Mariana J., Leflunomide Aventis Pharma, Current Opinion in investigation Drugs 2001 pp. 222-230 vol. 2(2)."><meta name="citation_reference" content="Menor et al, J. Pharm. Soc. Wisconsin, pp. 33-38, 1999.*"><meta name="citation_reference" content="Miljkovic, Dj. et al., Leflunomide Inhibits Activation of Inducible Nitric Oxide Synthase in Rat Astrocytes, Brain Research (2001) pp. 331-338, vol. 889."><meta name="citation_reference" content="Raymond D. Adams, et al., &quot;Multiple Sclerosis and Allied Demyelinating Diseases&quot;, in Principles of Neurology, (1997), pp. 902-921, McGraw-Hill, New York."><meta name="citation_reference" content="Schorlemmer H.U. et al., Treatment of Acute And Chronic Relapsing Experimental Allergic Encephalomyelitis (EAE) By The Malononitrilamides MNA 279 and MNA 715, Int J. Tissue React (1997, pp. 64, vol. 19, No. 1-2), abstract 73."><meta name="citation_patent_number" content="US:6794410"><meta name="citation_patent_application_number" content="US:10/113,078"><link rel="canonical" href="http://www.google.com/patents/US6794410"/><meta property="og:url" content="http://www.google.com/patents/US6794410"/><meta name="title" content="Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis"/><meta name="description" content="The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis."/><meta property="og:title" content="Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("DqrpU4jlOdDMsASPw4HQBA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407464522.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("GBR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("DqrpU4jlOdDMsASPw4HQBA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407464522.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("GBR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6794410?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6794410"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=t79oBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6794410&amp;usg=AFQjCNFL2M8RKjFoFm_ppFTrl9bJd274sQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6794410.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6794410.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20020177623"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US6794410"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6794410" style="display:none"><span itemprop="description">The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis....</span><span itemprop="url">http://www.google.com/patents/US6794410?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis" title="Patent US6794410 - Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6794410 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/113,078</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Sep 21, 2004</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 1, 2002</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 5, 2001</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US20020177623">US20020177623</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20030223960">US20030223960</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10113078, </span><span class="patent-bibdata-value">113078, </span><span class="patent-bibdata-value">US 6794410 B2, </span><span class="patent-bibdata-value">US 6794410B2, </span><span class="patent-bibdata-value">US-B2-6794410, </span><span class="patent-bibdata-value">US6794410 B2, </span><span class="patent-bibdata-value">US6794410B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Joseph+Wettstein%22">Joseph Wettstein</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Aventis+Pharmaceuticals+Inc.%22">Aventis Pharmaceuticals Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6794410.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6794410.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6794410.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (24),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (13),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (13),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (7),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6794410&usg=AFQjCNEmE7GNscTMHOgwT7xtylMu3JFF7w">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6794410&usg=AFQjCNGGOqVCRA9XfZroBJa0EfUI11xd7Q">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6794410B2%26KC%3DB2%26FT%3DD&usg=AFQjCNF2niRU5wPs5mGC0DzkiMl5t9EdMQ">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT72392963" lang="EN" load-source="patent-office">Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis</invention-title></span><br><span class="patent-number">US 6794410 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50725567" lang="EN" load-source="patent-office"> <div class="abstract">The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00001.png"> <img id="EMI-C00001" file="US06794410-20040921-C00001.TIF" wi="187.93215" he="62.17155" img-content="chem" img-format="tif" alt="Figure US06794410-20040921-C00001" src="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00001.png" class="patent-full-image" width="751" height="248"> </a> </div> <attachments> <attachment idref="CHEMCDX-00001" attachment-type="cdx" file="US06794410-20040921-C00001.CDX"> </attachment> <attachment idref="CHEMMOL-00001" attachment-type="mol" file="US06794410-20040921-C00001.MOL"> </attachment> </attachments> </chemistry> </div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(1)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6794410B2/US06794410-20040921-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(1)</span></span></div><div class="patent-text"><div mxw-id="PCLM8737777" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6794410-B2-CLM-00001" class="claim">
      <div class="claim-text">1. A method of treating multiple sclerosis which comprises administering to a patient having multiple sclerosis a therapeutically effective amount of a compound of Formula I, its stereoisomer, or a pharmaceutically acceptable salt thereof, <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00005.png"> <img id="EMI-C00005" file="US06794410-20040921-C00005.TIF" wi="187.70535" he="62.17155" img-content="chem" img-format="tif" alt="Figure US06794410-20040921-C00005" src="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00005.png" class="patent-full-image" width="750" height="248"> </a> </div> <attachments> <attachment idref="CHEMCDX-00005" attachment-type="cdx" file="US06794410-20040921-C00005.CDX"> </attachment> <attachment idref="CHEMMOL-00005" attachment-type="mol" file="US06794410-20040921-C00005.MOL"> </attachment> </attachments> </chemistry> </div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54301947" lang="EN" load-source="patent-office" class="description">
    <p>This application claims the benefit of U. S. Provisional Application No. 60/281,685 filed Apr. 5, 2001 and Great Britain application No. 0123571.2, filed Oct. 2, 2001.</p>
    <heading>FIELD OF THE INVENTION</heading> <p>The present invention relates to methods of treating multiple sclerosis. In particular, the present invention relates to the treatment of multiple sclerosis with (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, commonly known as teriflunomide.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide (teriflunomide) has the structure illustrated in Formula I: <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00002.png"> <img id="EMI-C00002" file="US06794410-20040921-C00002.TIF" wi="187.93215" he="62.17155" img-content="chem" img-format="tif" alt="Figure US06794410-20040921-C00002" src="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00002.png" class="patent-full-image" width="751" height="248"> </a> </div> <attachments> <attachment idref="CHEMCDX-00002" attachment-type="cdx" file="US06794410-20040921-C00002.CDX"> </attachment> <attachment idref="CHEMMOL-00002" attachment-type="mol" file="US06794410-20040921-C00002.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>It is an active metabolite of the disease-modifying, antirheumatic drug 5-methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide commonly known as leflunomide, the structure of which is shown in Formula II. Leflunomide was first disclosed generically in U.S. Pat. No. 4,087,535, issued on May 2, 1978 and specifically in U.S. Pat. No. 4,284,786, issued on Aug. 18, 1981, wherein it was disclosed that the compound could be used for the treatment of multiple sclerosis. The aforementioned patents are both incorporated herein by reference. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00003.png"> <img id="EMI-C00003" file="US06794410-20040921-C00003.TIF" wi="175.23135" he="89.78445" img-content="chem" img-format="tif" alt="Figure US06794410-20040921-C00003" src="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00003.png" class="patent-full-image" width="700" height="359"> </a> </div> <attachments> <attachment idref="CHEMCDX-00003" attachment-type="cdx" file="US06794410-20040921-C00003.CDX"> </attachment> <attachment idref="CHEMMOL-00003" attachment-type="mol" file="US06794410-20040921-C00003.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide (teriflunomide,Formula I) use in treating chronic graft-versus-host disease has been disclosed in U.S. Pat. No. 4,965,276 issued on Oct. 23, 1990, incorporated herein by reference. U.S. Pat. No. 5,459,163 issued on Oct. 21, 1997 and U.S. Pat. No. 5,679,709 issued on Oct. 21, 1997 disclose compositions useful for treating autoimmune diseases in particular lupus erythematosus. Both of the aforementioned patents are incorporated herein by reference. Teriflunomide has been shown to produce antiproliferative effects on a wide variety of immune cells and cell lines (Cherwinski H. M., et al., J Pharmacol. Exp. Ther. 1995;272:460-8; Prkash A., et al., Drugs 1999;58(6):1137-66; Bartlett R. R. et al., Agent Action 1991;32(1-2):10-21). Additionally, it inhibits the enzyme dihydrooate dehydrogenase, an enzyme essential for the synthesis of pyrimidines (Bruneau J-M, et al., Biochem. J. 1998; 36:299-303).</p>
    <p>Multiple sclerosis (MS) is a debilitating, inflammatory, neurological illness characterized by demyelination of the central nervous system. The disease primarily affects young adults with a higher incidence in females. Symptoms of the disease include fatigue, numbness, tremor, tingling, dysesthesias, visual disturbances, dizziness, cognitive impairment, urologic dysfunction, decreased mobility, and depression. Four types classify the clinical patterns of the disease: relapsing-remitting, secondary progressive, primary-progressive and progressive-relapsing (S. L. Hauser and D. E. Goodkin, Multiple Sclerosis and Other Demyelinating Diseases in Harrison's Principles of Internal Medicine 14<sup>th </sup>Edition, vol. 2, Mc Graw-Hill, 1998, pp. 2409-2419).</p>
    <p>The exact etiology of MS is unknown; however, it is strongly suspected that the demyelination characteristic of the disease is the result of an autoimmune response perhaps triggered by an environmental insult, e.g. a viral infection. Specifically, it is hypothesized that MS is caused by a T-cell-mediated, autoimmune inflammatory reaction. The autoimmune basis is strongly supported by the fact that antibodies specific to myelin basic protein (MBP) have been found in the serum and cerebrospinal fluid of MS patients and these antibodies along with T-cells that are reactive to MBP and other myelin proteolipids increase with disease activity. Furthermore, at the cellular level it is speculated that T-cell proliferation and other cellular events, such as activation of B cells and macrophages and secretion of cytokines accompanied by a breakdown of the blood-brain barrier can cause destruction of myelin and oligodendrocytes. (R. A. Adams, M. V. Victor and A. H. Ropper eds, Principles of Neurology, Mc Graw-Hill, New York, 1997, pp.903-921). Progressive MS (primary and secondary may be based on a nuerodegenerative process occurring with demyelination.</p>
    <p>At the present time there is no cure for MS. Current therapies are aimed at alleviating the symptoms of the disease and arresting its progress, as much as possible. Depending upon the type, drug treatment usually entails the use of disease-modifying agents such as the interferons (interferon beta 1-a, beta 1-b and alpha 2), glatiramer acetate or corticosteroids such as methylprednisolone and prednisone. Also, chemotherapeutic agents such as methotrexate, azathioprine, cladribine cyclophosphamide and cyclosporine have been used. All of the above treatments have side-effect liabilities, little or no effect on fatigue and depression, limited effects on relapse rates and on ability to prevent exacerbation of the disease. Treatment with interferons may also induce the production of neutralizing antibodies, which may ultimately decrease the efficacy of this therapy. Therefore, there still exists a strong need for new drugs, which can be used alone or in combination with other drugs to combat the progression and symptoms of MS.</p>
    <heading>SUMMARY OF THE PRESENT INVENTION</heading> <p>The present invention is a method of treating multiple sclerosis in patients by administering a compound of Formula I or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount to treat the disease. The present invention also comprises a method of treating multiple sclerosis in patients by administering a combination of a compound of Formula I or a pharmaceutically acceptable salt thereof, with another compound known to be effective for the treatment of multiple sclerosis in therapeutically effective amounts to treat the disease.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>Terms used herein have the meanings defined in this specification.</p>
    <p>a) “Pharmaceutically acceptable salts” means either an acid addition salt or a basic addition salt, whichever is possible to make with the compounds of the present invention.</p>
    <p>“Pharmaceutically acceptable acid addition salt” is any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di- and tri-carboxylic acids. Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicyclic, 2-phenoxybenzoic, p-toluenesulfonic acid and sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid. Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated or substantially anhydrous form. In general, the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents and which in comparison to their free base forms, generally demonstrate higher melting points.</p>
    <p>“Pharmaceutically acceptable basic addition salts” means non-toxic organic or inorganic basic addition salts of the compounds of Formula I. Examples are alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium or barium hydroxides; ammonia, and aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline. The selection of the appropriate salt may be important so that the ester is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art.</p>
    <p>b) “Patient” means a warm blooded animal, such as for example rat, mice, dogs, cats, guinea pigs, and primates such as humans.</p>
    <p>c) “Treat” or “treating” means any treatment, including, but not limited to, alleviating symptoms, eliminating the causation of the symptoms either on a temporary or permanent basis, or preventing or slowing the appearance of symptoms and progression of the named disorder or condition.</p>
    <p>d) “Therapeutically effective amount” means an amount of the compound, which is effective in treating the named disorder or condition.</p>
    <p>e) “Pharmaceutically acceptable carrier” is a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the compound of the present invention in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient. One example of such a carrier is pharmaceutically acceptable oil typically used for parenteral administration.</p>
    <p>f) “Stereoisomers” is a general term for all isomers of the individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereoisomers).</p>
    <p>g) “Leflunomide” is the generic name for 5-methylisoxazole-4-carboxylic-(4-trifluoromethyl)-anilide.</p>
    <p>h) “Teriflunomide” is the generic name for (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide.</p>
    <p>The synthesis of the compound of Formula 1 has been disclosed, and is accomplished by methods that are well known to those skilled in the art. For example, U.S. Pat. No. 5,504,084, issued on Apr. 2, 1996, and U.S. Pat. No. 5,990,141, issued on Nov. 23, 1999 disclose methods of synthesis. The aforementioned patents are incorporated herein by reference. One synthesis as disclosed in U.S. Pat. No. 5,990,141 is illustrated in Scheme 1. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00004.png"> <img id="EMI-C00004" file="US06794410-20040921-C00004.TIF" wi="215.8002" he="214.35435" img-content="chem" img-format="tif" alt="Figure US06794410-20040921-C00004" src="//patentimages.storage.googleapis.com/US6794410B2/US06794410-20040921-C00004.png" class="patent-full-image" width="863" height="857"> </a> </div> <attachments> <attachment idref="CHEMCDX-00004" attachment-type="cdx" file="US06794410-20040921-C00004.CDX"> </attachment> <attachment idref="CHEMMOL-00004" attachment-type="mol" file="US06794410-20040921-C00004.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>In Scheme 1, step A commercially available cyanoacetic acid ethyl ester is reacted with commercially available 4-trifluoromethylaniline neat at elevated temperature to give cyanoacet-(4-trifluoromethyl)anilide. In step B, the product from step A is dissolved in tetrahydrofuran and reacted with NaH in acetonitrile followed by reaction with acetyl chloride to produce the compound of Formula I.</p>
    <p>One method of showing the utility of the present compound as a pharmaceutical that may be useful for the treatment of various conditions associated with MS is its ability to inhibit effects of experimental allergic encephalomyelitis in laboratory animals.</p>
    <p>Experimental allergic encephalomyelitis (EAE) is an animal model for MS, which entails inducing a T-cell-mediated autoimmune disease against myelin basic protein in certain susceptible mammalian species. The EAE model is an appropriate method for studying the inflammation of the brain and spinal cord associated with MS (see Bolton, C. Mult. Scler. 1995;1(3);143-9).</p>
    <p>In treating a patient afflicted with a condition described above, a compound of Formula (I) can be administered in any form or mode which makes the compound bioavailable in therapeutically effective amounts, including orally, sublingually, buccally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. One skilled in the art of preparing formulations can determine the proper form and mode of administration depending upon the particular characteristics of the compound selected for the condition or disease to be treated, the stage of the disease, the condition of the patient and other relevant circumstances. For example, see Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990), incorporated herein by reference.</p>
    <p>The compound of the present invention may be administered orally, for example, in the form of tablets, troches, capsules, elixirs, suspensions, solutions, syrups, wafers, chewing gums and the like and may contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials, which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.</p>
    <p>The compound of Formula I of this invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment or gel base. The base, for example, may comprise one or more of petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.</p>
    <p>The solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials.</p>
    <p>The dosage range at which the compound of Formula I exhibits its ability to act therapeutically can vary depending upon its severity, the patient, the formulation, other underlying disease states that the patient is suffering from, and other medications that may be concurrently administered to the patient. Generally, the compound of Formula I will exhibit their therapeutic activities at dosages of between about 0.001 mg/kg of patient body weight/day to about 100 mg/kg of patient body weight/day.</p>
    <p>All cites to publications and patents herein are hereby incorporated by reference.</p>
    <heading>DESCRIPTION OF THE DRAWING</heading> <p>FIG. 1 shows the effect of teriflunomide on symptoms in the Rat Experimental Allergic Encephalomyelitis (EAE) at 3 different doses when administered orally (p.o.) as compared to vehicle and dexamethasone.</p>
    <p>The following example is being presented to further illustrate the invention. However, it should not be construed as limiting the invention in any manner.</p>
    <heading>EXAMPLE</heading> <heading>Rat Experimental Allergic Encephalomyelitis (Rat EAE)</heading> <p>Experimental allergic encephalomyelitis (EAE) is a T-cell-mediated autoimmune disease of the nervous system that develops in susceptible animals following sensitization with either whole spinal cord homogenate or a component (myelin basic protein). The EAE rodent model is an appropriate tool for studying the inflammation of the brain and spinal cord observed in MS patients. In rodents, injection of whole spinal cord or spinal cord components such as myelin basic protein induces an autoimmune response based on the activation of T-lymphocytes. Clinical disease typically becomes manifest around day 8-10 after inoculation, observed as a broad spectrum of behavioral anomalies ranging from mild gait disturbances and tail atony to complete paralysis and death. Weight loss typically occurs. In animals that survive, spontaneous recovery occurs, accompanied by variable recovery of most motor function. Depending on the species, allergen, and methodology used, animals tested by the EAE model may experience a single (acute EAE) or several (chronic relapsing EAE) attacks. Several treatment paradigms may be used: the drug or treatment of choice may be administered before immunization, during the nonsymptomatic period or during the clinical disease.</p>
    <p>Animals:</p>
    <p>Female Lewis rats, 160-220 g (Charles River)</p>
    <p>Antigen:</p>
    <p>Whole Guinea Pig spinal cord (Harlan Biosciences).</p>
    <p>Complete Freund's adjuvant H37 Ra [1 mg/ml Mycobacterium Tuberculosis H37 Ra] (Difco).</p>
    <p>Additional antigen:</p>
    <p>Mycobacterium Tuberculosis (Difco).</p>
    <p>Bordetella Pertussis [Heat Killed] (Difco).</p>
    <heading>Antigen Preparation: (for Approximately 720 Animals)</heading> <p>1. Weigh 5 grams of frozen guinea pig spinal cord.</p>
    <p>2. Add 5 g spinal cord to 5 ml 0.9% saline (1 g/ml) in a round bottom centrifuge tube</p>
    <p>3. Homogenize on ice with the Tissue-tech until the tissue is completely disrupted (approximately 5 minutes).</p>
    <p>4. Add 10 ml Complete Freund's adjuvant H37 Ra supplemented with 200 mg Mycobacterium Tuberculosis (20 mg/ml Complete Freund's adjuvant H37 Ra).</p>
    <p>5. Extract homogenate/adjuvant from tube by sucking it into a 10 ml syringe fitted with an 18 gauge emulsifying needle.</p>
    <p>6. Emulsify between two 30 ml glass syringes until it becomes difficult to continue passing the material through the needle. (Approximately 5 minutes {there must be no separation between the oil phase and the aqueous phase}).</p>
    <p>7. Use immediately or keep on ice until needed (not more than 30 min) (do not freeze).</p>
    <heading>Protocol</heading> <p>1. Female Lewis rats (Charles River) are given free access to food and water and should be acclimated a minimum of 3 days before use in experiments.</p>
    <p>2. Rats weighing 160 and 220 grams are initially induced with 5% isoflurane (Aerrane, Fort Dodge), 30% O<sub>2</sub>, 70% N<sub>2</sub>O for 2-5 minutes.</p>
    <p>3. The rat is then placed onto a circulating water heating blanket (Gaymar) (dorsal surface up) and into the nose cone for spontaneous respiration of anesthetic gases. The isoflurane is reduced to 2%.</p>
    <p>4. Two subcutaneous injections (0.1 ml each) of either antigen or normal saline are made into ventral surface of the hind paws.</p>
    <p>5. The animals are removed from the nose cone, weighed and numbered.</p>
    <p>6. The rats are allowed to awake from anesthesia and are placed into individual cages.</p>
    <p>7. The animals are observed daily for signs of EAE induction (see criteria below)</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="35pt" align="left"> </colspec> <colspec colname="2" colwidth="182pt" align="left"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">STAGE: 0</td>
                <td class="description-td">NORMAL</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 1</td>
                <td class="description-td">Abnormal gate and tail atony</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 2</td>
                <td class="description-td">Mild but definite weakness of one or both hind legs</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 3</td>
                <td class="description-td">Severe weakness of one or both hind legs or mild ataxia</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 4</td>
                <td class="description-td">Severe paraparesis and minimal hind leg movement</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 5</td>
                <td class="description-td">No hind leg movement and paraplegia</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 6</td>
                <td class="description-td">Moribund state with no spontaneous movement and impaired</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">respiration.</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Increasing degree of front leg involvement and urinary and</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">fecal incontinence may also occur</td>
              </tr> <tr class="description-tr"> <td class="description-td">STAGE: 7</td>
                <td class="description-td">DEATH</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>Treatment was begun on day 10 after immunization. Since the disease symptoms in this model typically appear 10-11 days after inoculation, this time point may be considered to represent the initial phase of an acute episode of MS. It is judged that this delay of the start of treatment mimics the clinical situation more closely than the traditionally used protocols where drugs are administered at the time of, or even before, inoculation (Teitelbaum D. et al., Proc Natl Acad Sci USA 1999; 96: 3842-3847 and Brod S. A., et al., Ann Neurol 2000; 47: 127-131)</p>
    <p>The effect of teriflunomide on symptoms of EAE in rat at various doses is illustrated in FIG. <b>1</b>. Dexamethasone is included in the figure for comparison.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4061767">US4061767</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 3, 1976</td><td class="patent-data-table-td patent-date-value">Dec 6, 1977</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Cyano acetic acid anilide derivatives, process for their manufacture and compositions containing these compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4087535">US4087535</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 3, 1976</td><td class="patent-data-table-td patent-date-value">May 2, 1978</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">5-Methyl-isoxazole-4-carboxylic acid anilides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4284784">US4284784</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 22, 1980</td><td class="patent-data-table-td patent-date-value">Aug 18, 1981</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Process for the preparation of 4-methyl thiazole</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4284786">US4284786</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 1979</td><td class="patent-data-table-td patent-date-value">Aug 18, 1981</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Rheumatic diseases antipyretics, analgesics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4351841">US4351841</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 3, 1981</td><td class="patent-data-table-td patent-date-value">Sep 28, 1982</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Pharmaceutical preparation and method of treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4965276">US4965276</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 1986</td><td class="patent-data-table-td patent-date-value">Oct 23, 1990</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Administering 4-trifluoromethylanilide of 5-methylisoxazole-4-carboxylic acid and/or n-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4965278">US4965278</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 21, 1989</td><td class="patent-data-table-td patent-date-value">Oct 23, 1990</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5268382">US5268382</a></td><td class="patent-data-table-td patent-date-value">Apr 17, 1992</td><td class="patent-data-table-td patent-date-value">Dec 7, 1993</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5459163">US5459163</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 13, 1993</td><td class="patent-data-table-td patent-date-value">Oct 17, 1995</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Medicament to combat autoimmune diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5679709">US5679709</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Oct 21, 1997</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide or salts, used for reduction of b-cell produced self-antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5714514">US5714514</a></td><td class="patent-data-table-td patent-date-value">Sep 16, 1996</td><td class="patent-data-table-td patent-date-value">Feb 3, 1998</td><td class="patent-data-table-td ">Hoechst Aktiegesellschaft</td><td class="patent-data-table-td ">2-Cyano-3-mercaptocrotonamides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5780592">US5780592</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 1996</td><td class="patent-data-table-td patent-date-value">Jul 14, 1998</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Transplant, antitumor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5856330">US5856330</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 1997</td><td class="patent-data-table-td patent-date-value">Jan 5, 1999</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5981536">US5981536</a></td><td class="patent-data-table-td patent-date-value">Oct 20, 1998</td><td class="patent-data-table-td patent-date-value">Nov 9, 1999</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Use of xanthine derivatives for the modulation of apoptosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5990141">US5990141</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 1995</td><td class="patent-data-table-td patent-date-value">Nov 23, 1999</td><td class="patent-data-table-td ">Sugen Inc.</td><td class="patent-data-table-td ">Administering 5-methyl-isoxazole-4-carboxylic acid-n-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-n-(4-trifluoro-methyl)phenyl-2-butenamide; antitumor,-carcinogenic and proliferative agents; kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6011051">US6011051</a></td><td class="patent-data-table-td patent-date-value">Jul 23, 1997</td><td class="patent-data-table-td patent-date-value">Jan 4, 2000</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Use of isoxazole and crotonamide derivatives for the modulation of apoptosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6060494">US6060494</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 1998</td><td class="patent-data-table-td patent-date-value">May 9, 2000</td><td class="patent-data-table-td ">Hoechst Marion Roussel Deutschland Gmbh</td><td class="patent-data-table-td ">Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6133301">US6133301</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 1998</td><td class="patent-data-table-td patent-date-value">Oct 17, 2000</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">Pharmaceuticals for the treatment of rejection reactions in organ transplantations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020006945">US20020006945</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 1997</td><td class="patent-data-table-td patent-date-value">Jan 17, 2002</td><td class="patent-data-table-td ">Aventis Pharma Deutschland Gmbh</td><td class="patent-data-table-td ">Immunology diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020022646">US20020022646</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 8, 2001</td><td class="patent-data-table-td patent-date-value">Feb 21, 2002</td><td class="patent-data-table-td ">Ilya Avrutov</td><td class="patent-data-table-td ">Method for systhesizing leflunomide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0896537A1?cl=en">EP0896537A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 1997</td><td class="patent-data-table-td patent-date-value">Feb 17, 1999</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993018776A1?cl=en">WO1993018776A1</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 1993</td><td class="patent-data-table-td patent-date-value">Sep 30, 1993</td><td class="patent-data-table-td ">Chiesi Farma Spa</td><td class="patent-data-table-td ">Combinations of compounds having antiviral activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994024095A1?cl=en">WO1994024095A1</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 1994</td><td class="patent-data-table-td patent-date-value">Oct 27, 1994</td><td class="patent-data-table-td ">Abbott Lab</td><td class="patent-data-table-td ">Immunosuppressive agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000033876A1?cl=en">WO2000033876A1</a></td><td class="patent-data-table-td patent-date-value">Dec 1, 1999</td><td class="patent-data-table-td patent-date-value">Jun 15, 2000</td><td class="patent-data-table-td ">Aventis Pharma Gmbh</td><td class="patent-data-table-td ">Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Amitabh Prakash, et al., "<a href='http://scholar.google.com/scholar?q="Leflunomide%2C+A+Review+of+its+Use+in+Active+Rheumatoid+Arthritis"'>Leflunomide, A Review of its Use in Active Rheumatoid Arthritis</a>", (1999), Drugs, vol. 58 (6), pp. 1137-1164.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anthony S. Fauci, et al., "<a href='http://scholar.google.com/scholar?q="Mutliple+Sclerosis+and+Other+Demyelinating+Disease"'>Mutliple Sclerosis and Other Demyelinating Disease</a>", in Harrison's Principles of Internal Medicine, 14&lt;th &gt;Edition, (1994), vol. 2, pp. 2409-2419, McGraw-Hill, New York.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anthony S. Fauci, et al., "<a href='http://scholar.google.com/scholar?q="Mutliple+Sclerosis+and+Other+Demyelinating+Disease"'>Mutliple Sclerosis and Other Demyelinating Disease</a>", in Harrison's Principles of Internal Medicine, 14th Edition, (1994), vol. 2, pp. 2409-2419, McGraw-Hill, New York.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Arvana Tablets, Prescription information, Apr. 2002.*</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bertolini, Giorgio et al., A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppresive Drug, J. Med. Chem. 1997, pp. 2011-2016, vol. 40.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">C. Bolton, "<a href='http://scholar.google.com/scholar?q="Recent+Advances+in+the+Pharmacological+Control+of+Experimental+Allergic+Encephalomyelitis+%28EAE%29+and+the+Implications+for+Multiple+Sclerosis+Treatment"'>Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment</a>", (1995), Multiple Sclerosis, vol. 1, pp. 143-149.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holly M. Cherwinski, et al., "<a href='http://scholar.google.com/scholar?q="The+Immunosuppressant+Leflunomide+Inhibits+Lymphocyte+Progression+Through+Cell+Cycle+by+a+Novel+Mechanism"'>The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism</a>", (1995),J. Pharmacol. Exp. Therap., vol. 272 (1), pp. 460-468.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J.M. Bruneau, et al., "<a href='http://scholar.google.com/scholar?q="Purification+of+Human+Dihydro-Orotate+Dehydrogenase+and+Its+Inhibition+by+A77+1726%2C+the+Active+Metabolite+of+Leflunomide"'>Purification of Human Dihydro-Orotate Dehydrogenase and Its Inhibition by A77 1726, the Active Metabolite of Leflunomide</a>", Biochem. J. (1998), vol. 336, pp. 299-303.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kaplan, Mariana J., Leflunomide Aventis Pharma, Current Opinion in investigation Drugs 2001 pp. 222-230 vol. 2(2).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Menor et al, J. Pharm. Soc. Wisconsin, pp. 33-38, 1999.*</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miljkovic, Dj. et al., Leflunomide Inhibits Activation of Inducible Nitric Oxide Synthase in Rat Astrocytes, Brain Research (2001) pp. 331-338, vol. 889.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raymond D. Adams, et al., "<a href='http://scholar.google.com/scholar?q="Multiple+Sclerosis+and+Allied+Demyelinating+Diseases"'>Multiple Sclerosis and Allied Demyelinating Diseases</a>", in Principles of Neurology, (1997), pp. 902-921, McGraw-Hill, New York.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schorlemmer H.U. et al., Treatment of Acute And Chronic Relapsing Experimental Allergic Encephalomyelitis (EAE) By The Malononitrilamides MNA 279 and MNA 715, Int J. Tissue React (1997, pp. 64, vol. 19, No. 1-2), abstract 73.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120208880">US20120208880</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 16, 2012</td><td class="patent-data-table-td patent-date-value">Aug 16, 2012</td><td class="patent-data-table-td ">Sanofi</td><td class="patent-data-table-td ">(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4&#39;-trifluormethylphenyl)-amide tablet formulations with improved stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2277515A1?cl=en">EP2277515A1</a></td><td class="patent-data-table-td patent-date-value">Jul 10, 2009</td><td class="patent-data-table-td patent-date-value">Jan 26, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2314291A1?cl=en">EP2314291A1</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 2009</td><td class="patent-data-table-td patent-date-value">Apr 27, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis</td><td class="patent-data-table-td ">Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008079270A2?cl=en">WO2008079270A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 19, 2007</td><td class="patent-data-table-td patent-date-value">Jul 3, 2008</td><td class="patent-data-table-td ">Michael Briskin</td><td class="patent-data-table-td ">Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011005907A1?cl=en">WO2011005907A1</a></td><td class="patent-data-table-td patent-date-value">Jul 8, 2010</td><td class="patent-data-table-td patent-date-value">Jan 13, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011049792A1?cl=en">WO2011049792A1</a></td><td class="patent-data-table-td patent-date-value">Oct 13, 2010</td><td class="patent-data-table-td patent-date-value">Apr 28, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011150014A1?cl=en">WO2011150014A1</a></td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td patent-date-value">Dec 1, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for treating brain atrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011150017A1?cl=en">WO2011150017A1</a></td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td patent-date-value">Dec 1, 2011</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of terilfunomide for maintaining fatigue level of a patient having multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012018704A1?cl=en">WO2012018704A1</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2011</td><td class="patent-data-table-td patent-date-value">Feb 9, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for treating multiple sclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012061060A1?cl=en">WO2012061060A1</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2011</td><td class="patent-data-table-td patent-date-value">May 10, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for treating brain atrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012061062A1?cl=en">WO2012061062A1</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2011</td><td class="patent-data-table-td patent-date-value">May 10, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for improving motor function</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012116128A1?cl=en">WO2012116128A1</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2012</td><td class="patent-data-table-td patent-date-value">Aug 30, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for treating cognitive impairment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012162339A1?cl=en">WO2012162339A1</a></td><td class="patent-data-table-td patent-date-value">May 23, 2012</td><td class="patent-data-table-td patent-date-value">Nov 29, 2012</td><td class="patent-data-table-td ">Sanofi-Aventis U.S. Llc</td><td class="patent-data-table-td ">Use of teriflunomide for reducing occurrence of relapses requiring healthcare resources</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S521000">514/521</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031165000">A61K31/165</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031277000">A61K31/277</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/277">A61K31/277</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=t79oBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/165">A61K31/165</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/165</span>, <span class="nested-value">A61K31/277</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIM 1 IS CANCELLED.NEW CLAIMS 2-22 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20111014</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 31, 2011</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110916</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">POWER OF ATTORNEY;ASSIGNOR:AVENTIS PHARMACEUTICALS INC.;REEL/FRAME:027151/0666</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANOFI-AVENTIS U.S. LLC, NEW JERSEY</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 21, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 7, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 3, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMACEUTICALS INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WETTSTEIN, JOSEPH;REEL/FRAME:014393/0926</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010608</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AVENTIS PHARMACEUTICALS INC. 300 SOMERSET BLVD.BRI</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WETTSTEIN, JOSEPH /AR;REEL/FRAME:014393/0926</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 22, 2003</td><td class="patent-data-table-td ">DJ</td><td class="patent-data-table-td ">All references should be deleted, no patent was granted</td><td class="patent-data-table-td "></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0Z5jOnUm5WXDtmnab3r0HP_x-ZkQ\u0026id=t79oBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1k5cacYeWSMyr082c9vYYzRgPI2w\u0026id=t79oBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3xN6v6p2nnZRF_nrXI2bmdQfhS_w","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Use_of_Z_2_cyano_3_hydroxy_but_2_enoic_a.pdf?id=t79oBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0BGCPzV4YA6fTqsS5jnGydwVV0sQ"},"sample_url":"http://www.google.com/patents/reader?id=t79oBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>